Based on the analysis of the core signaling pathways for ABC and considering the protein/gene expressions [75,80], the biomarkers NOTCH1 and TF FOXO1 are selected as the drug targets for the specific oncogenic mechanisms of ABC. This evidence concerns the gene NOTCH1 and aneurysmal bone cyst.